Day One Biopharmaceuticals is a biopharmaceutical company developing and commercializing targeted therapies for life-threatening diseases across all ages. Its first commercial product, OJEMDA (tovorafenib), an oral once-weekly RAF kinase inhibitor, was FDA-approved in April 2024 for relapsed or refractory pediatric low-grade glioma. The company also has DAY301, an ADC targeting PTK7, in Phase 1 trials, and acquired Mersana Therapeutics in January 2026, adding Emi-Le, a B7-H4-directed ADC for adenoid cystic carcinoma.
Q2 FY2026 — expected 2026-08-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-066956 | EDGAR | 120K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026654 | EDGAR | 117K words |
| 2024-02-26 | 2023-12-31 | 0000950170-24-020212 | EDGAR | 115K words |
| 2023-03-06 | 2022-12-31 | 0000950170-23-006269 | EDGAR | — |
| 2022-03-07 | 2021-12-31 | 0000950170-22-002959 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001193125-25-264649 | EDGAR | 82K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-103012 | EDGAR | 80K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064436 | EDGAR | 77K words |
| 2024-10-30 | 2024-09-30 | 0000950170-24-118958 | EDGAR | 84K words |
| 2024-08-02 | 2024-06-30 | 0000950170-24-089945 | EDGAR | 78K words |
| 2024-05-06 | 2024-03-31 | 0000950170-24-053612 | EDGAR | 70K words |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059485 | EDGAR | 78K words |
| 2023-08-07 | 2023-06-30 | 0000950170-23-039118 | EDGAR | 75K words |
| 2023-05-01 | 2023-03-31 | 0000950170-23-016046 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022667 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014859 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009734 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-06 | 0001193125-26-095174 | EDGAR | 53K words |
| 2026-03-02 | 0001193125-26-084267 | EDGAR | 6K words |
| 2026-02-24 | 0001193125-26-066926 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009834 | EDGAR | 6K words |
| 2026-01-06 | 0001104659-26-001127 | EDGAR | 7K words |
| 2025-11-24 | 0001193125-25-292096 | EDGAR | 6K words |
| 2025-11-13 | 0001104659-25-110812 | EDGAR | 5K words |
| 2025-11-04 | 0001193125-25-264608 | EDGAR | 2K words |
| 2025-10-10 | 0001193125-25-237072 | EDGAR | 1K words |
| 2025-08-05 | 0000950170-25-102969 | EDGAR | 2K words |
95 total filings indexed. 68 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001845337 |
| Ticker | DAWN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/DAWN (~200 tokens, structured JSON with cryptographic provenance)